An anti-ErbB2 fully human antibody circumvents trastuzumab resistance

Trastuzumab, an anti-HER2/ErbB2 humanized antibody, has shown great clinical benefits in ErbB2-positive breast cancer treatment. Despite of its effectiveness, response rate to trastuzumab is limited and resistance is common. Here, we developed a new anti-ErbB2 antibody, denoted as H2-18, which was i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Lu, Qiong, Wang, Lingfei, Zhang, Yajun, Yu, Xiaojie, Wang, Chao, Wang, Huajing, Yang, Yang, Chong, Xiaodan, Xia, Tian, Meng, Yanchun, Wang, Yuxiao, Lu, Cuihua, Zhou, Lijun, Li, Bohua
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341862/
https://ncbi.nlm.nih.gov/pubmed/27564098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11562
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia